Table 4.
Cox regression analysis for overall survival in elderly patients
| Variable | Multivariate |
Univariate |
||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p-value | HR | 95% CI | p-value | |
| B Symptom (yes vs. no) | 0.709 | 0.311-1.615 | 0.413 | 0.403 | 0.218-0.746 | 0.004 |
| Ann Arbor stage (I/II vs. III/IV) | 0.601 | 0.204-1.765 | 0.354 | 1.423 | 1.008-1.861 | 0.010 |
| Performance status (ECOG 0-1 vs. ≥ 2) | 0.454 | 0.223-0.922 | 0.029 | 2.867 | 1.586-5.182 | < 0.001 |
| LDH level (normal vs. elevated) | 0.616 | 0.254-1.492 | 0.283 | 2.390 | 1.212-4.711 | 0.012 |
| No. of extranodal sites (0-1 vs. ≥ 2) | 0.864 | 0.426-1.730 | 0.684 | 1.825 | 1.007-3.308 | 0.047 |
| IPI score (0-2 vs. 3-5) | 0.596 | 0.156-2.227 | 0.449 | 3.137 | 1.715-5.738 | < 0.001 |
| Bone marrow involvement (yes vs. no) | 1.922 | 0.848-4.353 | 0.117 | 1.236 | 0.632-2.418 | 0.536 |
| Bulky tumor (yes vs. no) | 1.970 | 0.763-5.089 | 0.161 | 0.782 | 0.363-1.684 | 0.529 |
| DID (< 10 mg/m2/wk vs. ≥ 10 mg/m2/wk) | 1.597 | 0.607-4.202 | 0.343 | 0.446 | 0.206-0.965 | 0.040 |
HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; IPI, International Prognostic Index; DID, dose intensity of doxorubicin.